Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis

Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis

Hepatocellular carcinoma (HCC), the third major cause of cancer mortality, can result from non-alcoholic steatohepatitis (NASH). Due to limited efficacy of drugs approved for HCC and no drug available yet for NASH, identification of new effective treatments is crucial. Here, we investigated whether...

Full description

Bibliographic Details
Main Authors: Joseph Kuo, Sonia Simón Serrano, Alvar Grönberg, Ramin Massoumi, Magnus Joakim Hansson, Philippe Gallay
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Pharmacology
Subjects:
histology
inflammation
cytokines
steatosis
tumor burden
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01129/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01129/full

Similar Items